PARP inhibitors (PARPi) such as niraparib have been approved for different malignancies with genomic alteration in germline breast cancer susceptibility gene (BRCA) and DNA damage response (DDR) pathway genes. This evidence concerns the gene PARP1 and breast carcinoma.